Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avexa Of Australia Reports Good Results With HIV Drug

This article was originally published in PharmAsia News

Executive Summary

Australian drug maker Avexa reports positive results from a Phase II study of its apricitabine HIV drug to treat patients unresponsive to GlaxoSmithKline's Epivir (lamivudine). Avexa CEO Julian Chick said the study showed the firm's drug to be at least as good as the safest HIV drug on the market. The study reported the drug reduced the AIDS-causing virus to insignificant levels in 89 percent of patients. Avexa seeks to license marketing rights to a larger partner so it can complete the studies this year. (Click here for more

You may also be interested in...



Coronavirus Update: Neurimmune, Ethris, Fujifilm, Brii In New Bids Against COVID-19, Reata, Ionis Delay Studies

Neurimmune and Ethris partner on inhaled therapy. Reata, Ionis and others delay trials, Brii announces China antibody alliance, Fujifilm starts favipiravir trials.

Spring Shopping: Ping An Bets On Shionogi, TCMs In Coronavirus Aftermath

China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.

EU Scientific Committee Affirms Safety Of Anti-Dandruff Zinc Pyrithione Under Threat Of Cosmetic Ban

The Scientific Committee for Consumer Safety upholds that zinc pyrithione is safe for use in rinse-off anti-dandruff hair products at levels up to 1%. In recent years, the cosmetics industry has pushed for a 2% ceiling on ZPT content in that capacity – with considerable inroads made. Where that proposal now stands vis-à-vis the ingredient’s pending CMR 1B classification and shifting political sands is uncertain.

UsernamePublicRestriction

Register

SC071035

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel